Detail page

Knowledge Web

Person

Andreas Viardot (1968-)

Name	Andreas Viardot
Time	1968- (Date of birth and death)
Academic degree	Dr. med.
Further information	Diss. Medizinische Fakultät an der Universität Ulm (2002); Habil.-Schr. Medizinische Fakultät (Fach Innere Medizin) an der Universität Ulm (2010)
Record type	Person
GND-Identifier	123546605
Record ID	123546605
Involved in show all Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis : The UNFOLDER Study A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial Bedeutung des genomischen Screening bei Keimzentrumslymphomen (follikuläre und diffus-großzellige B-Zell-Non-Hodgkin-Lymphome) : Vergleich der prognostischen Relevanz von Bänderungsanalyse, comparativer genomischer Hybridisierung und microarraybasierter Analyseverfahren Sekundäre genetische Aberrationen bei follikulären Lymphomen : Stellenwert von Chromosomenbänderungsanalyse und comparativer genomischer Hybridisierung (CGH)

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Andreas Viardot (1968-)

Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma

General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia

Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis : The UNFOLDER Study

A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial

UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial

Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma

Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma

Bedeutung des genomischen Screening bei Keimzentrumslymphomen (follikuläre und diffus-großzellige B-Zell-Non-Hodgkin-Lymphome) : Vergleich der prognostischen Relevanz von Bänderungsanalyse, comparativer genomischer Hybridisierung und microarraybasierter Analyseverfahren

Sekundäre genetische Aberrationen bei follikulären Lymphomen : Stellenwert von Chromosomenbänderungsanalyse und comparativer genomischer Hybridisierung (CGH)